Standard BioTools Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 17, 2026, specifically the Company's 2026 Annual Meeting of Stockholders. Standard BioTools Inc. (Nasdaq: LAB) is a Delaware corporation headquartered in Boston, Massachusetts.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial statement items.
Material Changes and Voting Results
On the record date of April 24, 2026, the Company had 390,368,119 shares of common stock issued and outstanding. Approximately 86.04% of total voting power was represented at the Annual Meeting. Stockholders approved the following proposals:
- Election of Directors: Michael Egholm, Ph.D., Thomas Carey, and Eli Casdin were elected as Class I directors to serve until the 2029 Annual Meeting.
- Executive Compensation: The advisory vote to approve named executive officer compensation for the year ended December 31, 2025, was approved.
- Independent Auditor: The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026 was ratified.
- Equity Incentive Plan: The 2026 Equity Incentive Plan was approved.
- ESPP Amendment: An amendment to the 2017 Employee Stock Purchase Plan was approved, increasing the number of shares reserved for issuance by 1,200,000 shares.
Guidance, Outlook, and Risks
This filing does not provide management commentary on future guidance, outlook, risks, contingencies, or unusual items. It strictly reports the outcomes of the stockholder vote and incorporates by reference the definitive proxy statement filed on April 27, 2026, for further details on the plans and compensation arrangements.
Investor Verification Checklist
- Verify the full text of the 2026 Equity Incentive Plan (Exhibit 10.1) and the Amended ESPP (Exhibit 10.2) to understand dilution implications and vesting terms.
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 27, 2026, for detailed descriptions of the approved plans and executive compensation specifics.
- Confirm the broker non-vote count of 86,119,046 shares, which represented a significant portion of the outstanding shares but did not affect the outcome of the proposals.
- Check subsequent filings for the Company's next quarterly or annual report to obtain actual financial performance metrics absent from this 8-K.